CABALETTA BIO INC (CABA) Stock Price, Quote, News and Overview
NASDAQ:CABA - Nasdaq - US12674W1099 - Common Stock - Currency: USD
CABA Quote, Performance and Key Statistics
1.96
-0.1 (-4.85%)
The current stock price of CABA is 1.96 USD. In the past month the price decreased by -21.6%. In the past year, price decreased by -91.82%.
CABA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.17 | 360.64B | ||
| AMGN | AMGEN INC | 15.63 | 166.32B | ||
| GILD | GILEAD SCIENCES INC | 24.08 | 138.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1660.86 | 123.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.63 | 77.97B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.11B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.04B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.58B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.58 | 20.59B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.73 | 15.99B |
Related stock screener links
About CABA
Company Profile
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 154 full-time employees. The company went IPO on 2019-10-25. The firm is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Company Info
CABALETTA BIO INC
2929 Arch Street, Suite 600
PHILADELPHIA PENNSYLVANIA 19104 US
CEO: Steven Nichtberger
Employees: 137
Company Website: https://www.cabalettabio.com/
Investor Relations: https://www.cabalettabio.com/investors
Phone: 12677593100
CABALETTA BIO INC / CABA FAQ
What is the stock price of CABALETTA BIO INC today?
The current stock price of CABA is 1.96 USD. The price decreased by -4.85% in the last trading session.
What is the ticker symbol for CABALETTA BIO INC stock?
The exchange symbol of CABALETTA BIO INC is CABA and it is listed on the Nasdaq exchange.
On which exchange is CABA stock listed?
CABA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CABALETTA BIO INC stock?
18 analysts have analysed CABA and the average price target is 21.01 USD. This implies a price increase of 972.04% is expected in the next year compared to the current price of 1.96. Check the CABALETTA BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CABALETTA BIO INC worth?
CABALETTA BIO INC (CABA) has a market capitalization of 95.80M USD. This makes CABA a Micro Cap stock.
How many employees does CABALETTA BIO INC have?
CABALETTA BIO INC (CABA) currently has 137 employees.
What are the support and resistance levels for CABALETTA BIO INC (CABA) stock?
CABALETTA BIO INC (CABA) has a resistance level at 2.42. Check the full technical report for a detailed analysis of CABA support and resistance levels.
Should I buy CABALETTA BIO INC (CABA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CABA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CABA, evaluating the profitability, health, valuation and growth aspects
- CABALETTA BIO INC (CABA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CABALETTA BIO INC (CABA) Sales and EPS estimates to see what analysts future expectations are.
- CABALETTA BIO INC (CABA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CABALETTA BIO INC (CABA) Insider and Institutional Ownership to learn about the owners and their transactions.
- CABALETTA BIO INC (CABA) Stock Chart to make your own analysis
- CABALETTA BIO INC (CABA) Latest news and press-releases to stay up to date.
Does CABALETTA BIO INC (CABA) stock pay dividends?
CABA does not pay a dividend.
When does CABALETTA BIO INC (CABA) report earnings?
CABALETTA BIO INC (CABA) will report earnings on 2025-03-13, after the market close.
What is the Price/Earnings (PE) ratio of CABALETTA BIO INC (CABA)?
CABALETTA BIO INC (CABA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.15).
What is the Short Interest ratio of CABALETTA BIO INC (CABA) stock?
The outstanding short interest for CABALETTA BIO INC (CABA) is 13.2% of its float. Check the ownership tab for more information on the CABA short interest.
CABA Technical Analysis
CABA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CABA. No worries on liquidiy or solvency for CABA as it has an excellent financial health rating, but there are worries on the profitability.
CABA Financial Highlights
Over the last trailing twelve months CABA reported a non-GAAP Earnings per Share(EPS) of -2.15. The EPS decreased by -25.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.96% | ||
| ROE | -59.78% | ||
| Debt/Equity | 0 |
CABA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to CABA. The Buy consensus is the average rating of analysts ratings from 18 analysts.